MIRA Pharmaceuticals shareholders reelect board
MIRA Pharmaceuticals’ 2026 annual meeting achieved a 63.06% quorum, electing all director nominees and ratifying Salberg & Company, P.A. as auditor.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
MIRA Pharmaceuticals, Inc. held its 2026 Annual Meeting of Stockholders on September 11, 2026, with 26,499,076 common shares present in person or by proxy out of 42,022,087 outstanding, representing a 63.06% quorum. Stockholders elected all five nominated directors to serve until the next annual meeting and until their successors are elected and qualified. Stockholders also approved the ratification of Salberg & Company, P.A. as independent registered public accounting firm for the year ending December 31, 2026, and approved a proposal allowing adjournment of the meeting, if necessary, to solicit additional proxies for the director and auditor proposals.
8-K Event Classification
Key Figures
Key Terms
Record Date financial
quorum financial
broker non-votes financial
independent registered public accounting firm financial
adjournment of the Annual Meeting financial
Emerging growth company regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What matters did MIRA (MIRA) stockholders vote on at the 2026 Annual Meeting?
Were all director nominees elected at MIRA (MIRA)’s 2026 Annual Meeting?
Which audit firm did MIRA (MIRA) stockholders ratify for fiscal year 2026?
Did MIRA (MIRA) stockholders approve the adjournment proposal at the 2026 Annual Meeting?
How many votes did MIRA (MIRA) CEO Erez Aminov receive for director election?
AI-generated analysis. How Rhea-AI works. Not financial advice.